Discussion
Loading...

Post

Log in
  • About
  • Code of conduct
  • Privacy
  • Users
  • Instances
  • About Bonfire
The Japan Times
@thejapantimes@mastodon.social  ·  activity timestamp 21 hours ago

A health ministry panel approved a plan to cut the price of Lecanemab, an Alzheimer's drug that Japanese drugmaker Eisai and U.S. industry peer Biogen codeveloped, by 15% in Japan starting Nov. 1. https://www.japantimes.co.jp/news/2025/08/07/japan/science-health/japan-alzheimer-drug-price-cut/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #alzheimer039s #medicine #pharmaceuticals#eisai #health

  • Copy link
  • Flag this post
  • Block
Log in

bonfire.cafe

A space for Bonfire maintainers and contributors to communicate

bonfire.cafe: About · Code of conduct · Privacy · Users · Instances
Bonfire social · 1.0.0-rc.2.6 no JS en
Automatic federation enabled
  • Explore
  • About
  • Members
  • Code of Conduct